ELISA检测肿瘤患者血清64DP

据报道64DP是一种与肿瘤相关的人血清DNA结合蛋白质,其现有的定量测定方法略嫌繁琐粗糙。本文采用亲和层析法纯化的兔抗64DP抗体,建立了简便灵敏的酶免疫测定法(ELISA)。部分样本经ELISA和火箭电泳两种方法平行测定,证明两者有良好的相关性。对70例恶性肿瘤及86例正常对照血清的测定结果,肿瘤组平均64DP水平显著高于对照组,其中尤以肝癌、胃癌及肺癌的增高更为显著。对非肿瘤其它疾病患者的检测发现感染和外伤也能造成血清64DP的迅速增加。本研究表明血清64DP的改变不仅仅局限于恶性肿瘤,它具有急性期反应蛋白质的特征。这使64DP作为肿瘤标志物应用于临床受到一定限制。     

肌动蛋白存在于蚕豆细胞核和染色体中

以兔抗肌动蛋白抗体为一抗,FTTC偶联的羊抗兔IgG抗体为二抗进行间接免疫荧光实验,观察到蚕豆(Vicia faba L.)根端分生组织中完整的细胞核和染色体均有明亮荧光。用抗肌动蛋白抗体和蛋白A-胶体金进行标记的免疫电镜实验结果表明,金颗粒分布在蚕豆细胞核中,集缩染色质和核仁中金颗粒较多。经DNaseI消化和2 mol/L NaCl处理得到去除DNA和组蛋白的细胞核和染色体。免疫荧光实验结果指出,去除DNA和组蛋白的细胞核和染色体与抗肌动蛋白抗体呈阳性反应。上述结果说明,肌动蛋白不仅存在于完整的蚕豆细胞核和染色体中,而且存在于去除DNA和组蛋白的蚕豆细胞核和染色体中。另外,用抗原肌球蛋白抗体所做的免疫荧光标记结果表明,原肌球蛋白也存在于蚕豆细胞核和染色体中。对高等植物细胞核和染色体以及核骨架和染色体骨架是否含有肌动蛋白等问题进行了讨论。     

一种具有抑制糜蛋白酶活性的血清DNA结合蛋白质的纯化和理化特性

 本文采用离子交换层析,DNA亲和层析和硫酸铵盐析三步从人血清中分离纯化了一种肿瘤相关DNA结合蛋白质(64DP)。本方法较简便,产率提高。经SDS聚丙烯酰胺凝胶电泳和免疫电泳鉴定纯度符合要求。SDS聚丙烯酰胺凝胶电泳测定分子量为64,000。等电聚焦电泳测得等电点在4.2左右。醋酸纤维膜电泳和转移电泳表明其为一种α_1球蛋白。过碘酸西夫氏糖蛋白染色呈阳性反应。氨基酸分析和酶抑制试验证实64DP与α_1抗縻蛋白酶很相似。     

蝙蝠血清IgG的纯化及兔抗蝙蝠IgG酶标抗体的制备

目的纯化蝙蝠血清IgG,制备兔抗蝙蝠IgG酶标抗体。方法采用亲和层析纯化法纯化蝙蝠血清IgG,SDS-PAGE电泳鉴定蝙蝠IgG纯度。免疫大白兔制备兔抗蝙蝠IgG抗血清,免疫双扩散法测定抗血清效价,亲和层析纯化法纯化抗血清IgG。用改良过碘酸钠标记法制备兔抗蝙蝠IgG酶标抗体,直接ELISA和Western blot法对兔抗蝙蝠IgG酶标抗体进行工作浓度测定。结果纯化的蝙蝠血清IgG,其SDS-PAGE测定纯度大于95%;免疫大白兔所制备的抗血清免疫双扩散效价为1∶64;用改良过碘酸钠标记法制备兔抗蝙蝠IgG酶标抗体,其直接ELISA和Western blot工作浓度分别为1∶12800和大于1∶2000。结论制备了蝙蝠血清IgG的抗血清和酶标抗体,为蝙蝠的血清学检测体系提供了技术和资源储备。     

兔抗金黄地鼠酶标抗体的制备及应用

目的 纯化金黄地鼠血清IgG,制备兔抗金黄地鼠酶标抗体(IgG-HRP),开展金黄地鼠仙台病毒的初步检测.方法 采用亲和层析纯化法纯化金黄地鼠IgG,用SDS- PAGE电泳测定IgG纯度并制备兔抗金黄地鼠IgG抗体(second antibody,Ab2);用免疫双扩散法检测抗血清效价后,再用亲和层析纯化抗血清IgG( Ab2);采用改良过碘酸钠标记法制备兔抗金黄地鼠酶标抗体( rabbit anti-hamster IgG-HRP);用直接ELISA和Western-blot法对兔抗金黄地鼠IgG酶标抗体进行工作浓度测定;应用金黄地鼠酶标抗体对金黄地鼠仙台病毒进行酶免检测(IEA).结果 金黄地鼠血清IgG纯度达95％;兔抗金黄地鼠IgG抗体(Ab2)免疫双扩散效价为1(:)64;兔抗金黄地鼠IgG -HRP经直接ELISA和Western-Blot测定工作浓度分别为1∶5000和1∶2000;酶免(IEA)效价为1:2000.结论 高效快速纯化了金黄地鼠IgG,制备了金黄地鼠IgG-HRP,为金黄地鼠病原微生物的血清学检测提供了条件.     

C群脑膜炎球菌多糖-rP64K结合物的制备及免疫原性

用1-氰基-4-二甲基氨基吡啶·四氟化硼(CDAP)活化C群脑膜炎球菌多糖(GCMP),以己二酰肼(ADH)作为连接子,与重组B群脑膜炎球菌外膜蛋白64 KD(rP64K)在碳二亚胺的(EDAC)作用下结合,制备GCMP-P64K结合物。纯化后免疫NIH小鼠,用间接ELISA法检测小鼠血清中抗GCMPIgG抗体水平,并GCMP-TT结合物比较载体诱导的免疫抑制。所制备多糖-蛋白结合物(GCMP-P64K)保持了GCMP抗原特异活性,结合物免疫小鼠后可诱生比多糖单独免疫更高水平的GCMP血清IgG抗体,并能形成免疫记忆,为研究理想载体蛋白提供了新的思路。     

有关检测雌激素、孕激素、雌激素受体和孕激素受体水平的技术性探讨

应用兔抗雌二醇抗体、兔抗孕酮抗体,鼠抗雌激素受体和鼠抗孕激素受体抗体来检测乳腺癌等病例,结果显示,兔抗雌二醇抗体和兔抗孕酮抗体所标记的病例的阳性物主要见于癌细胞胞浆,应用石蜡切片且不经任何方法处理的结果为最好。应用鼠抗雌激素受体抗体和鼠抗孕激素受体抗体和鼠抗孕激素受体抗体的病例,阳性物见于癌细胞的胞核上,但需要用隔水热抗原修复法经较长时间的处理后,方能获得最佳结果。     

SLE血清中抗-DNA抗体分离和性质的研究

本文用国产高分子树脂(T)接枝小牛胸腺DNA,通过亲合层析从系统性红斑狼疮SLE患者血清中纯化出抗-ds DNA抗体和抗-ss DNA抗体。酶联免疫吸附分析(ELISA)的研究表明:SLE抗-DNA抗体和DNA结合的差异性很大,是高度非均一性的。抗-ss DNA抗体不仅组成成分比抗-ds DNA抗体复杂,ss DNA/抗-ssDNA亲合能力也明显高于ds DNA/抗-ds DNA。纯化的抗-DNA抗体以IgG类抗体占主导,同时也有其它类型抗体存在(例如IgM等)。抗-ds DNA抗体有较抗-ss DNA抗体高的IgG含量(两者的IgG/IgM分别是7.0和4.0),说明IgG抗-DNA抗体更倾向于同dsDNA结合。     

富含半胱氨酸蛋白61多克隆抗体的制备及其在子痫前期胎盘检测中的作用

目的:制备兔抗人富含半胱氨酸蛋白(Cyr61)多克隆抗体,并用该抗体检测Cyr61蛋白在重度子痫前期(PE)和正常妊娠胎盘中的差异表达.方法:用RT-PCR法从Hela细胞中克隆Cyr61全长mRNA,并在大肠杆菌中表达获得重组蛋白,免疫新西兰白兔得到兔抗人Cyr61多克隆抗体.然后用此抗体对14例重度子痫前期胎盘进行检测,并与孕周匹配的14例正常胎盘比较.结果:Cyr61DNA测序结果与参考序列一致;Western blot竞争法证实制备的兔抗Cyr61抗体与商品化的羊抗Cyr61抗体有共同的靶点;用制备的兔抗人Cyr61蛋白抗体Western blot检测发现,在重度PE胎盘中Cyr61蛋白含量较正常胎盘含量降低(14.2±1.0 vs.29.2±1.1 P＜0.05).结论:本研究成功地在大肠杆菌中表达出Cyr61融合蛋白,并制备了特异性高的兔抗人Cyr61抗体.重度PE胎盘中Cyr61蛋白表达水平降低.     

ORP4L 多克隆抗体的制备及其在蛋白质组学研究中的应用

目的:原核表达并纯化人氧化固醇结合蛋白相关蛋白4(ORP4L)肽段,制备兔抗人ORP4L多克隆抗体,并利用其进行蛋白质组学研究。方法:应用PCR技术扩增人ORP4L 382-485氨基酸(ORP4Lm)的基因序列并插入到PGEX-4T-1载体中,在大肠杆菌RosettaTM(DE3)中表达融合蛋白GST-ORP4Lm。利用所表达的融合蛋白中含有的GST标签进行亲和纯化。用所获得的纯化蛋白免疫新西兰大白兔,获得兔抗人ORP4L多克隆抗体。用Western blotting检测抗体免疫特异性。将亲和纯化后的抗体偶联到CNBr-actived sepharose beads上,利用免疫沉淀的方法,通过质谱仪分析鉴定可能与ORP4L存在相互作用的蛋白质。通过West-ern blotting进一步确证特异性的相互作用蛋白。结果:在大肠杆菌中表达并纯化了GST-ORP4Lm重组蛋白,用其免疫新西兰大兔,成功制备了相应兔源多克隆抗体,Western blotting证实该抗体可以特异识别内源性及外源性的ORP4L蛋白。质谱分析和Western blotting的结果表明所制备的多克隆抗体可以用于蛋白质组学研究。结论:利用重组的GST-ORP4Lm融合蛋白成功制备了有良好特异性的ORP4L多克隆抗体,并可将其用于ORP4L的蛋白组学研究。     

Purification of a serum DNA binding protein (64DP) with a molecular weight of 64,000 and its diagnostic significance in malignant diseases

A DNA binding protein with a molecular weight of 64,000(64DP) has been purified to homogeneity from human serum, and its quantitative assay has been developed. The average level of serum 64DP in 30 normal controls was 41.4 μg/ml, whereas it was 175 μg/ml in 87 patients with untreated malignant disease. Furthermore it was found to be elevated in all tested patients, 8 cases, with carcinoma in early stages. Serum 64DP has been found to be different from C3DP, CEA^# or α-FP^#, and it appears that this protein might prove to be a useful tumor marker in malignant diseases.     

ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF

The tumor suppressor ARF inhibits cell growth in response to oncogenic stress in a p53-dependent manner. Also, there is an increasing appreciation of ARF's ability to inhibit cell growth via multiple p53-independent mechanisms, including its ability to regulate the E2F pathway. We have investigated the interaction between the tumor suppressor ARF and DP1, the DNA binding partner of the E2F family of factors (E2Fs). We show that ARF directly binds to DP1. Interestingly, binding of ARF to DP1 results in an inhibition of the interaction between DP1 and E2F1. Moreover, ARF regulates the association of DP1 with its target gene, as evidenced by a chromatin immunoprecipitation assay with the dhfr promoter. By analyzing a series of ARF mutants, we demonstrate a strong correlation between ARF's ability to regulate DP1 and its ability to cause cell cycle arrest. S-phase inhibition by ARF is preceded by an inhibition of the E2F-activated genes. Moreover, we provide evidence that ARF inhibits the E2F-activated genes independently of p53 and Mdm2. Also, the interaction between ARF and DP1 is enhanced during oncogenic stress and "culture shock." Taken together, our results show that DP1 is a critical direct target of ARF.     

Generation of a conditionally self-eliminating HAC gene delivery vector through incorporation of a tTAVP64 expression cassette

Human artificial chromosome (HAC)-based vectors represent an alternative technology for gene delivery and expression with a potential to overcome the problems caused by virus-based vectors. The recently developed alphoid^tetO-HAC has an advantage over other HAC vectors because it can be easily eliminated from cells by inactivation of the HAC kinetochore via binding of chromatin modifiers, tTA or tTS, to its centromeric tetO sequences. This provides a unique control for phenotypes induced by genes loaded into the HAC. The alphoid^tetO-HAC elimination is highly efficient when a high level of chromatin modifiers as tetR fusion proteins is achieved following transfection of cells by a retrovirus vector. However, such vectors are potentially mutagenic and might want to be avoided under some circumstances. Here, we describe a novel system that allows verification of phenotypic changes attributed to expression of genes from the HAC without a transfection step. We demonstrated that a single copy of tTA^VP64 carrying four tandem repeats of the VP16 domain constitutively expressed from the HAC is capable to generate chromatin changes in the HAC kinetochore that are not compatible with its function. To adopt the alphoid^tetO-HAC for routine gene function studies, we constructed a new TAR-BRV- tTA^VP64 cloning vector that allows a selective isolation of a gene of interest from genomic DNA in yeast followed by its direct transfer to bacterial cells and subsequent loading into the loxP site of the alphoid^tetO-HAC in hamster CHO cells from where the HAC may be MMCT-transferred to the recipient human cells.     

Malignancy-associated DNA-binding protein C3DP from human serum. Further characterization and purification of C3DP retaining its DNA-binding affinity.

C3DP, a malignancy-associated DNA-binding protein from human serum[1], was purified to homogeneity without loss of its DNA-binding affinity. For this purpose normal human serum was submitted to affinity chromatography on Con A-Sepharose and DNA-cellulose and to preparative polyacrylamide gel electrophoresis. The purified C3DP was identified by immunodiffusion and sodium dodecylsulfate polyacrylamide gel electrophoresis and it was shown to bind to DNA by DNA-cellulose chromatography. The isoelectric point of C3DP was determined to 4.9 by isoelectric focusing.     

Chromatin receptors for thyroid hormones. Interactions of the solubilized proteins with DNA.

Thyroid hormone-responsive tissues contain chromatin "receptor" proteins that are concentrated in chromatin subfractions enriched in DNA. These receptors appear to be DNA-binding proteins. In the present study, we utilized a DNA-cellulose binding assay to further examine the interactions of solubilized receptors with DNA. [125I]Triiodothyronine associates with receptors bound to DNA-cellulose, whereas free [I]triiodothyronine and [125I]triiodothyronine associated with other proteins does not. The DNA-receptor interactions appear to be strong enough to exist at physiological ionic strength since binding is 50% maximal ag 0.175 M NaCl and is only partly inhibited by Ca2+ and Mg2+ in the 1 to 5 mM range. Most, if not all, of the receptors are capable of DNA binding, and there are at least 80,000 receptor binding sites/diploid DNA (assuming one triiodothyronine binding site/receptor). Binding of the receptor-[125I]triiodothyronine complexes to other DNAs and analogs was examined using a competition assay. There is similar binding by native and denatured DNA, gy eukaryotic DNA from different species and by prokaryotic DNA (Bacillus subtilis). Binding by natural DNAs is more avid than by cytoplasmic RNA, nuclear RNA, poly(dA-dT)-poly(dA-dT), or poly(dG-dC)-poly(dG-dC). Under these conditions, binding by tRNA and poly(dA) is insignificant, and the nucleotide monomers ATP and GTP have no detectable binding. These studies support the idea that the thyroid hormone receptor is a DNA-binding protein and that the interaction is a major determinant for receptor localization in chromatin. The competition studies suggest that the polynucleotide composition and/or conformation can have marked influences on the binding, and that multiple orders of binding affinity can exist. The presence of specific sequences cannot be excluded. However, the finding that receptors bind extensively and tightly to DNA suggests that receptors in chromatin may randomly bind to any available DNA, resulting in some of the receptors being at physiologically unimportant sites. If so, the several thousand hormone receptors present in each target cell may be required to enhance the possibility that some of the receptors are present at the actual sites of action.